Apellis Pharmaceuticals (APLS)
NASDAQ:APLS
Want to see APLS full AI Analyst Report?
APLS Stock Chart & Stats
$40.90
-$1.37(-3.96%)
At close: 4:00 PM EST
$40.90
-$1.37(-3.96%)
Day’s Range― - ―
52-Week Range$16.10 - $41.00
Previous CloseN/A
Volume215.04K
Average Volume (3M)7.41M
Market Cap
$5.25B
Enterprise Value$5.26B
Total Cash (Recent Filing)$467.76M
Total Debt (Recent Filing)$486.31M
Price to Earnings (P/E)―
Beta1.77
Next Earnings
Jul 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.17
Shares Outstanding128,021,270
10 Day Avg. Volume5,313,017
30 Day Avg. Volume7,414,349
Financial Highlights & Ratios
PEG Ratio-1.27
Price to Book (P/B)8.55
Price to Sales (P/S)3.15
P/FCF Ratio70.33
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue5.24
Enterprise Value/Gross Profit5.84
Enterprise Value/Ebitda75.20
Forecast
1Y Price Target
$39.59Price Target Upside-3.21% Downside
Rating ConsensusHold
Number of Analyst Covering19
EPS Forecast (FY)-1.12
Revenue Forecast (FY)$864.35M
Bulls Say, Bears Say
Bulls Say
Pipeline Expansion PotentialAnalyst notes ongoing pivotal trials to expand Empaveli into additional rare kidney conditions could broaden the drug's market opportunity and support future growth if trials meet endpoints.
Strategic ValidationAnalyst states the acquisition validates Apellis's complement platform and its nephrology commercial infrastructure, which could boost investor confidence in the technology and strategic positioning.
Upside From Contingent PaymentsAnalyst highlights contingent value rights tied to Syfovre global sales as potential additional upside for shareholders if the drug achieves meaningful commercial traction.
Bears Say
Contingent Payments UncertaintyAnalyst judges the contingent milestone payments as aspirational and unlikely under base sales projections, reducing the realistic financial upside from the transaction.
Deal Caps Near-term UpsideAnalyst downgraded the stock to Neutral on the view that the agreed acquisition price will likely limit upside for existing shareholders, pushing the share price toward the deal consideration.
Regulatory And Commercial Execution RiskAnalyst warns that uncertain regulatory approvals, potential weak commercial adoption, or competitive advances could prevent sales inflection needed to earn milestone payments and harm valuation.
Apellis Pharmaceuticals News
APLS FAQ
What was Apellis Pharmaceuticals’s price range in the past 12 months?
Apellis Pharmaceuticals lowest stock price was $16.10 and its highest was $41.00 in the past 12 months.
What is Apellis Pharmaceuticals’s market cap?
Apellis Pharmaceuticals’s market cap is $5.25B.
When is Apellis Pharmaceuticals’s upcoming earnings report date?
Apellis Pharmaceuticals’s upcoming earnings report date is Jul 30, 2026 which is in 86 days.
How were Apellis Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Apellis Pharmaceuticals overvalued?
According to Wall Street analysts Apellis Pharmaceuticals’s price is currently Overvalued.
Does Apellis Pharmaceuticals pay dividends?
Apellis Pharmaceuticals does not currently pay dividends.
What is Apellis Pharmaceuticals’s EPS estimate?
Apellis Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Apellis Pharmaceuticals have?
Apellis Pharmaceuticals has 128,021,270 shares outstanding.
What happened to Apellis Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Apellis Pharmaceuticals?
Currently, no hedge funds are holding shares in APLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Apellis Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$39.59 (-3.21% Downside)
$39.59 (-3.21% Downside)
Blogger Sentiment
Neutral
APLS Sentiment 50%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 129.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $8.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.6%
Last 30 Days >0.1%
Last 30 Days >0.1%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
124.72%
12-Months-Change
Fundamentals
Return on Equity
8.20%
Trailing 12-Months
Asset Growth
21.49%
Trailing 12-Months
Company Description
Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
APLS Company Deck
APLS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized multiple commercial and scientific positives: robust EMPAVELI early launch metrics (>5% market penetration, 267 start forms), SYFOVRE injection growth (~17% YoY) and strong 5‑year clinical data, a progressing pipeline with upcoming readouts and regulatory milestones, and a solid cash position ($466M). Offsetting these strengths are near-term revenue headwinds from elevated free goods and high gross-to-net adjustments (mid‑to‑high‑20% range), seasonal and quarter-to-quarter variability for launches in ultra-rare populations, modestly higher 2026 operating expenses to fund pivotal trials, and a $94M convertible debt maturing in 2026. Overall, the highlights around commercial traction, data readouts, pipeline advancement and financial flexibility outweigh the challenges, though execution risks and revenue timing uncertainty remain.View all APLS earnings summariesAPLS Stock 12 Month Forecast
Average Price Target
$39.59
▼(-3.21% Downside)
Technical Analysis
Zai Lab
―
Crinetics Pharmaceuticals
―
―
Mirum Pharmaceuticals
―
MoonLake Immunotherapeutics
―
Ownership Overview
3.99% Insiders
18.55% Mutual Funds
1.43% Other Institutional Investors
54.54% Public Companies and
Individual Investors